IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private...
PR Newswire·10d ago
More News
IceCure Medical Reports Positive Trial Results For ProSense Cryoablation System
(RTTNews) - IceCure Medical Ltd. (ICCM) on Wednesday, has reported favorable top-line results from its ICESECRET clinical trial, which assessed the ProSense Cryoablation System for the treatment of...
Nasdaq News: Markets·10d ago
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates IceCure Reports Positive 5-Year Top-Line Results from ICESECRET...
PR Newswire·11d ago
IceCure Medical Appoints Meir Peleg As CFO; Shares Rise In Pre-market
(RTTNews) - IceCure Medical Ltd. (ICCM), on Tuesday, appointed Meir Peleg as Chief Financial Officer, effective May 17...
Nasdaq News: Markets·12d ago
IceCure Appoints Meir Peleg as Chief Financial Officer
IceCure Appoints Meir Peleg as Chief Financial Officer IceCure Appoints Meir Peleg as Chief Financial Officer PR Newswire CAESAREA, Israel, March 24, 2026 Meir Peleg brings over 20 years of financial...
PR Newswire·12d ago
IceCure Medical (ICCM) Q4 2025 Earnings Transcript
IceCure Reports 2025 Full Year Financial & Operational Results
IceCure Reports 2025 Full Year Financial & Operational Results IceCure Reports 2025 Full Year Financial & Operational Results PR Newswire CAESAREA, Israel, March 17, 2026 Record 4th quarter and full...
PR Newswire·19d ago
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense Cryoablation in the Local Treatment of Low-Risk Breast Cancer
U.S. FDA Approves IceCure's Post-Marketing 'ChoICE' Study for ProSense Cryoablation in the Local Treatment of Low-Risk Breast Cancer U.S. FDA Approves IceCure's Post-Marketing 'ChoICE' Study for...
PR Newswire·25d ago
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 PR Newswire...
PR Newswire·26d ago
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends...